About 340 million patients with sexually transmitted infections (STIs) are annually registered in the world, including infections caused by Mycoplasma genitalium, which is an especially interesting infectious agent. This interest is due to the pronounced negative impact of the infection on human reproductive health, as well as rapidly developing resistance of M. genitalium to various pharmacological groups of antibacterial drugs. In particular, there were numerous attempts to use Doxycycline to eliminate this pathogen since 1981, when the role of M. genitalium in the development of non-gonococcal urethritis (NGU) was first evidenced. To date, the results of numerous long-term international research have demonstrated extremely low efficacy of doxycycline (no more than 30%) with respect to M. genitalium. Objective — the study was aimed at surveying the opinion of medical practitioners in the Moscow region on the tactics of management of patients with infections caused by M. genitalium, including range, single and course doses of prescribed etiotropic medications compared to the international and Russian clinical guidelines. Material and methods. We developed a «Doctor’s questionnaire« for this study containing a list of various questions about surveillance of patients with M. genitalium infection. Results. We analyzed the questionnaires completed by 69 urologists and dermatovenerologists at the Moscow Scientific and Practical Center for Dermatovenerology and Cosmetology, whose working experience ranged from 2 to 37 years. The results showed that only 1/3 of questioned doctors prescribed the polymerase chain reaction for M. genitalium to the patients who applied for STI screening regardless of the presence/absence of subjective and/or objective symptoms of urogenital diseases; another 1/3 of doctors prescribed the polymerase chain reaction only to patients with clinical signs of urogenital infectious and inflammatory diseases or sexual partners of persons with diagnosed M. genitalium infection. The remaining 1/3 of doctors prescribed the polymerase chain reaction to all patients who sought for medical advice. These results demonstrate the absence of a single point of view on the indications for screening for M. genitalium in the questioned specialists. At the same time, according to these results, all clinicians are aware of the important role of this infectious agent in the development of reproductive dysfunction in patients, since they believe that sexual partners of the patients with M. genitalium must be tested. Most respondent specialists prescribe treatment to a sexual partner only when he/her personally visits the doctor, which was also considered as a positive point. The information about the spectrum of drugs prescribed for elimination of M. genitalium is of greatest interest. Thus, 67 (97%) of 69 physicians believe that causal treatment should be administered in patients with diagnosed M. genitalium regardless of the presence or absence of clinical symptoms. Detailed analysis of treatment regimens administered in patients with M. genitalium infection showed that 36 (52%) of 69 doctors prefer administration of doxycycline at a dose of 100 mg BID for 10 days; 26 (38%) of 69 doctors prescribe josamycin at a dose of 500 mg TID for 10 days (which complies with clinical guidelines of the Russian Community of Dermotologists and Venereologists and does not comply in some respects with modern international approaches to the management of patients with M. genitalium infection). Conclusion. The obtained results of questionnaire survey of practicing dermatologists and venereologists in the Moscow region demonstrate the absence of a unified algorithm of management of patients with M. genitalium infection and the used treatment regimens often differ from corresponding modern scientific data obtained in clinical trials complying with the principles of evidence based medicine.